



TECHNICAL UPDATE to July 31st CUSTOMER LETTER

Re: Use of BD general use syringes in the compounding of low-concentration pharmaceutical dosages

Testing has revealed that the preparation of medications in reduced concentrations, typically for pediatric use, is more susceptible to active ingredient degradation than more typical dosage ranges.

BD continues to investigate this matter in collaboration with its suppliers, its customers and the FDA, and will provide updates as information becomes available.

Please contact the BD medical affairs staff for more information regarding the above. They can be reached at 201-847-4500 or drug_potency@bd.com.